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In Brief
Regulation of protein function via
intramolecular interactions—interactions
in cis—play an important role in the fine-
tuning of signaling processes, and their
disruption has been associated with
human diseases. Here, a computational
method is introduced that predicts the
presence of protein sequence elements
that mediate such interactions, and the
new method is used to investigate the
prevalence and disease-association of
these elements in the human context.
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Protein interactions incis that can activate or autoinhi-
bit protein function play an important role in the fine-
tuning of regulatory and signaling processes in the
cell, but thus farcis-regulatoryelements (CREs) inpro-
teinshavenotbeensystematically identifiedandstud-
ied.Here,we introduceacomputational tool that iden-
tifies intrinsically disordered protein segments that
contribute to protein function regulation via interac-
tions in cis. We apply this tool to estimate the preva-
lence of CREs in the human proteome and reveal
that cis regulation is enriched in several signaling
pathways, including the MAP kinase pathway, for
whichweprovide adetailedmapof its ‘‘cis regulome.’’
We also show that disease-causing mutations are
highly enriched in CREs, but not in motifs that classi-
cally mediate protein-protein interactions of disor-
dered protein segments. Our approach should facili-
tate the discovery and characterization of CREs in
proteins and the identification of disease-causing
mutations that disrupt protein regulation in cis.
INTRODUCTION
Transient intramolecular interactions between different parts of
the same polypeptide chain play key roles in the calibration of
numerous biological processes. Whereas such intramolecular
interactions can activate (Schaufele et al., 2005; Underbakke
et al., 2013; Zhou et al., 2001) or inhibit protein function (Pufall
and Graves, 2002), autoinhibitory interactions are more often
reportedandused toexplain theprinciplesof the regulationofpro-
tein function incis. Therefore,we introduce themainconcepts that
underlie our study with the help of autoinhibition, but these con-
ceptscanalsobeapplied toactivating intramolecular interactions.
Protein autoinhibition is achieved, in the simplest case, by the
intramolecular binding of an autoinhibitory module (AIM) to a
functional domain that is part of the same polypeptide chain (Fig-
ure 1A). Autoinhibitory interactions in cis provide an ‘‘on-site’’
way for switching the function of a protein domain off by stericor allosteric inhibition of substrate/binding partner access to cat-
alytic sites/binding surfaces (Kim et al., 2000; Ko and Prives,
1996; Lee et al., 2005; Padrick and Rosen, 2010; Pearson
et al., 2000; Pufall and Graves, 2002; Sto¨ven et al., 2000; Zhou
et al., 2004). Autoinhibition is generally relieved via posttransla-
tional modifications, binding of activating partners, or the irre-
versible proteolysis of the AIM. Alternatively, autoinhibition can
also be reinforced via binding of biomolecules or posttransla-
tional modifications.
Autoinhibition is often used to attenuate DNA-protein or pro-
tein-protein interactions. Prominent examples of proteins that
use autoinhibition to regulate interactions are Ets-1 (Pufall
et al., 2005), a member of the ETS family of transcription factors
that are frequently used as downstream effectors in signal trans-
duction cascades, andMDMX (Chen et al., 2015), a key regulator
of the cellular availability and activity of p53. Enzyme activity is
also frequently regulated via inhibitory interactions in cis. Many
kinases (e.g., FAK; Lietha et al., 2007) are fine-tuned in their ac-
tivity via interactions with AIMs. In the complex network of inter-
connected signaling pathways, the cis-acting inhibition of pro-
teins prevents their spurious activation and allows pathway
activity regulation via the integration of multiple inputs, e.g.,
through various posttranslational modifications and ligands.
Given the importance for signal integration, it is not surprising
that alterations of protein interactions in cis have been causally
linked to various diseases. In the relatively common develop-
mental disorder Noonan syndrome (dwarfism, heart defect), for
instance, autoinhibition of the Ras-guanine nucleotide exchange
factor SOS1 is lost due to missense mutations (Niault et al.,
2009). This disruption of autoinhibition results in unchecked
Ras signaling in the downstreamMAPK pathway. Altered autoin-
hibition has also been associated with various types of cancer.
For instance, the kinase AKT1 is involved in cell proliferation,
growth and angiogenesis (Parikh et al., 2012). The kinase domain
(KD) of AKT1 is autoinhibited in its activity by intramolecular inter-
actions with a pleckstrin homology (PH) domain. Somatic muta-
tions that were found in various cancers affect residues located
at the KD-PH interface. In vitro and in vivo experiments showed
that these AKT1 mutants are constitutively active and lead to
oncogenic signals (Parikh et al., 2012).
Restoration of autoinhibition has proven to be very success-
ful in the treatment of some cancers (Peterson and Golemis,
2004), making autoinhibited proteins an interesting target forCell Systems 2, 89–100, February 24, 2016 ª2016 The Authors 89
Figure 1. Development of Cis-regPred, a Tool to Identify Disordered CREs
(A) Mechanism of cis regulation of protein function; here autoinhibition. A CRE binds to a functional domain in cis and inhibits its function. Autoinhibition can be
released or reinforced by multiple mechanisms.
(B) Feature score assignment. Shown are some scores for a window of size 5 centered on the amino acid Thr. Some scores are position-specific (e.g., disorder
propensity), and some are averages of all properties within the window (e.g., number of phosphorylation sites) or the entire protein (e.g., protein globularity).
(C) Search for optimal MLR model parameters. Different window sizes and feature numbers were tested to find the combination that provided the highest AUC.
The different AUCs that were calculated are provided here as a function of window size and feature number. (Inlay) AUC of training datasets (a), cross-validation
sets (b), and test datasets (c) as a function of increasing feature numbers for a window size of 15. See also Figure S1 for details.
(D) Cis-regPred evaluation. ROC curves calculated for the test datasets.rational drug design. Unfortunately, protein sequence parts
that have autoinhibitory function—cis-regulatory function in
the more general sense—are so far discovered only by chance
through case-by-case experimental studies. To our knowledge,
no method has yet been developed that predicts which proteins
are regulated in cis and enables genome-wide screenings for
cis-regulatory elements (CREs) in proteins. Here, we introduce
Cis-regPred, a computational tool that uses primarily sequence
information to identify intrinsically disordered protein segments
that regulate protein function in cis (http://ssbio.cau.ac.kr/
cisregpred; Data S1).
RESULTS
Development of Cis-regPred
CREs can activate or autoinhibit protein function. Autoinhibited
proteins are more easily identifiable in a literature search. There-90 Cell Systems 2, 89–100, February 24, 2016 ª2016 The Authorsfore, we decided to assemble sets of proteins that contain AIMs,
train and evaluate ourmethod on them, and later test whether the
method would also identify activating CREs. Although indepen-
dently folded domains can act as AIMs, we recently revealed
that AIMs are often intrinsically disordered, and these AIMs are
distinct from structured ones by various properties (Trudeau
et al., 2013). These findings motivated us identifying features
that are enriched in disordered AIMs to pinpoint amino acid
residues in intrinsically disordered protein segments that are
involved in cis regulation. We used these features to train a mul-
tiple linear regression (MLR) model that predicts the location of
disordered CREs.
Specifically, we first assembled a positive set of 65 autoin-
hibited proteins (5,774 amino acids within disordered AIMs)
and a negative set of 467 proteins with structured AIMs or
intrinsically disordered segments that are known to interact
in trans via molecular recognition features (MoRFs), which
are short sequences stretches that undergo disorder-to-order
transitions upon binding (326,474 amino acids; see Supple-
mental Experimental Procedures and Table S1 for details).
Then, we identified 400 features that have the highest correla-
tion with the location of disordered AIMs—of 1,040 sequence-
position specific or window-averaged feature types (Figure 1B;
Table S3; Experimental Procedures; Supplemental Experi-
mental Procedures)—and used them to train the MLR. We
identified the optimal MLR model in an exhaustive feature se-
lection process in which we tested different numbers of top-
ranked features (f = 10–400) and window sizes (n = 3–41) as
input. The least absolute shrinkage and selection operator
(LASSO) method was applied to exclude unrelated features
(Ghosh and Chinnaiyan, 2005). This feature selection and the
MLR parameter optimization were performed in training only
(Walsh et al., 2015) and models assessed via 10-fold cross-
validation (Figure 1C; for more details see Experimental Proce-
dures). A window size of 15 and the use of 44 features pro-
vided the highest area under curve (AUC) (0.90) on the ten
cross-validation sets for the per-residue identification of disor-
dered CREs (see Table S4 for selected features). The AUC for
the per-protein prediction on the cross-validation sets, i.e.,
whether a protein contains a predicted CRE that overlaps
with a known CRE, is 0.80. A plot of the AUC as a function
of an increasing number of selected features (Figures 1C,
inset, and S1A) for the window size of 15 clearly shows that
the performance on the 10 cross-validation sets drops when
more than 44 features are used while the performance on
the actual training sets keeps increasing. Hence, models can
be improved up to 44 features but are fitted to noise in the
training sets when more features are used, i.e., the models
are overfitted beyond 44 features.
Among the features chosen for the MLR are several that we
previously found enriched in disordered AIMs such as phos-
phorylation sites and splicing sites (Trudeau et al., 2013). These
two features are also significantly more frequently associated
with the CREs than the MoRFs of the negative sets (Fig-
ure S1C). They are likely to be very important for the (in)activa-
tion of CREs (Hunter, 1995; Yu et al., 2010) or their tissue-spe-
cific expression (Buljan et al., 2012). The selection of intrinsic
disorder and various dipeptide sequences, of which half
contain charged or polar residues, is consistent with the higher
level of intrinsic disorder in CREs compared to MoRFs (Fig-
ure S1C). Such high levels of disorder may be advantageous
for the conformational changes that occur in the activity cycle
of CREs (Trudeau et al., 2013). Finally, the selection of the
net charge difference as a MLR feature, which when low indi-
cates that the CRE has a complementary sequence window
with opposite net charge (Figure S1D), may relate to the impor-
tance of electrostatics in the steering of the interactions of
intrinsically disordered segments (Hemsath et al., 2005; Wong
et al., 2013), in this case interactions in cis (for further informa-
tion on the selected features see Supplemental Experimental
Procedures).
Evaluation of Cis-regPred
We evaluated the performance of Cis-regPred on a test dataset
(16 positive and 62 negative proteins) not used in training (Table
S2; see Supplemental Experimental Procedures for details). Onthis test set, Cis-regPred achieves an AUC for the per-residue
and the per-protein prediction of 0.78 and 0.79, respectively
(Figure 1D). Importantly, the AUC is highest for a MLR that
uses 44 features, while it drops for models using higher feature
numbers (Figures 1C, inset, and S1B). For the actual predic-
tions, we decided to select a stringent cutoff (0.3) that provides
a high specificity in the identification of disordered CREs on
the training sets (see Experimental Procedures). At this cutoff,
Cis-regPred has an accuracy of 87.5% for the per-residue
prediction (sensitivity = 0.41 and specificity = 0.89) and a true
discovery rate (TDR) of 0.10 on the test set. The accuracy for
the per-protein prediction is 75.0% (sensitivity = 0.44, speci-
ficity = 0.84) and the TDR 0.44. The higher TDR of the per-pro-
tein prediction compared to the per-residue prediction reveals
that Cis-regPred has a high accuracy in determining whether
a protein has an intrinsically disordered CRE, although the exact
identification of the residues involved in cis regulation is less
accurate. However, one has to stress that the boundaries of
AIMs in our positive training and test sets are not always
well defined (see Experimental Procedures). More importantly,
training and testing reveal that Cis-regPred identifies between
32.3% (Experimental Procedures) and 43.8% of proteins with
known disordered CREs at a TDR of approximately 0.44–0.57.
These metrics are comparable to those found for state-of-the
art prediction methods for protein interactions in trans (Kotlyar
et al., 2015).
We illustrate the performance of Cis-regPred on two proteins
from the positive test set (Plk4 and CAMKK2) and two from the
negative set (Las17 and WASF1) (Figure 2). These four test pro-
teins have maximal sequence identities of 32%, 30%, 31%, and
33%with the proteins HMGA1, CAMKI, and WASP, respectively,
from the training set. When comparing the CRE regions only, the
sequence identities between these training and test protein pairs
are 19%, 17%, 15%, and 8%, respectively. Plk4 (polo-like ki-
nase 4) is a serine/threonine protein kinase that contains a CRE
between residues 318 and 380. This CRE autoinhibits Plk4 and
phosphorylation of residues S374 and S378 activates the kinase
(Klebba et al., 2015). Cis-regPred predicts that residues ranging
from position 305 to 384 are involved in cis regulation, which is
consistentwith the experimentally identifiedCRE.Thehumanpro-
tein CAMKK2 is predicted to contain disordered CREs at both
termini. The C-terminal CRE has been experimentally identified,
but the N-terminal CRE has not been tested yet inHomo sapiens.
However, the N-terminal region of rat CAMKK2 (not used in
training) has been shown to contain a CRE (Tokumitsu et al.,
2001) that has a high sequence identity (80.2%)with the predicted
N-terminalCREof the humanCAMKK2.ThehumanWASPprotein
is autoinhibited and part of our training dataset. Las17 is a yeast
homolog of WASP that has been experimentally shown not to be
autoinhibited (Rodal et al., 2003). Equally, WASF1, though similar
in its structure to WASP, is not autoinhibited either (Eden et al.,
2002). As can be seen in Figure 2, no disordered CREswere iden-
tified by Cis-regPred for both of these proteins. All proteins of the
test dataset are listed in Table S2, and their prediction profiles are
shown in Figures S2A–S2C or can be predicted with Cis-regPred
at http://ssbio.cau.ac.kr/cisregpred.
As mentioned before, CREs act not exclusively in an autoinhi-
bitory way and some cases of protein-activating intramolecular
interactions have been reported. As there are no known featuresCell Systems 2, 89–100, February 24, 2016 ª2016 The Authors 91
Figure 2. Prediction Profiles of Test Proteins
Prediction profiles of two autoinhibited proteins (Plk4 and CAMKK2) that contain a CRE, and two non-autoinhibited proteins (Las17 and WASF1) that contain no
CREs. More prediction profiles are shown in Figure S2.that a priori distinguish inhibiting from activating CREs in pro-
teins, Cis-regPred most likely can’t distinguish between them
and should also identify activating CREs despite being trained
only on AIMs. To test this hypothesis, we searched for intrinsi-
cally disordered protein segments that mediate activating, or
at least not inhibiting, intramolecular interactions. Figure S2D
shows that Cis-regPred identifies activating CREs correctly
in 4 of 5 proteins (CNG, Varnum and Zagotta, 1997; Sirt1,
Kang et al., 2011; Pan et al., 2012; CFTR, Bozoky et al., 2013; Os-
tedgaard et al., 2003; and Stat3, Zhang et al., 2002). Because we
could only find and analyze few proteins with intrinsically disor-
dered CREs that are not autoinhibiting, these results have to
be interpreted with care. However, they suggest that, consistent
with our hypothesis, Cis-regPred identifies CREs but cannot
assign an inhibitory function despite being trained on autoinhi-
bited proteins only.
Comparison with Motif Predicting Methods
A reliable comparison of Cis-regPred with other prediction
methods is not possible, because, to the best of our knowledge,
this is the first computational method to identify disordered
CREs. However, autoinhibited proteins with disordered AIMs
often are activated via interactions with partner proteins, most
likely mediated via MoRFs in the AIMs. Therefore, we tested92 Cell Systems 2, 89–100, February 24, 2016 ª2016 The Authorswhether CREs can simply be identified by predicting the location
of MoRFs. We tested this hypothesis by using the MoRF predic-
tors ANCHOR (Me´sza´ros et al., 2009) andMoRFCHiBi (Malhis and
Gsponer, 2015). The performance of our method is significantly
better than the one of ANCHOR and MoRFCHiBi (Table S5). The
per-protein sensitivities of ANCHOR and MoRFCHiBi are very
high, but their specificities are very low. The high sensitivity indi-
cates thatMoRFsare indeedoverlappingwithCREswhile the low
specificity shows that the MoRF prediction methods identify any
type of MoRFs whether close/within CREs or not; therefore, pro-
ducing many more false positives than Cis-regPred (Figure S3).
Consistentwith this fact,MoRFsite predictionswerenot selected
as a feature during the MLR tuning. Conversely, Cis-regPred
predicts MoRFs very poorly with an AUC of 0.379, indicating
that sequence windows that are top-scored by Cis-regPred are
mostly ‘‘non-MoRF’’ intrinsically disordered sequence parts.
Westress that the comparison of theperformance ofCis-regPred
with those of ANCHOR andMoRFCHiBi on the prediction of CREs
andMoRFs is not fair, because they were developed for different
purposes. However, these results confirm that Cis-regPred
identifies much fewer interaction-prone elements in intrinsically
disordered protein segments than MoRF predictors, and these
elements, although overlapping with MoRFs, have distinct
features.
Figure 3. Enrichment Analyses
(A) Enrichment of proteins with disordered CREs in
different KEGG pathways. Shown is the signifi-
cance (p values) of the enrichment. For compari-
son, enrichments of SLiM-containing proteins in
different KEGG pathways are also shown.
(B) Significance (p values) of the enrichment of
disease-associated mutations within disordered
CREs, within disordered SLiMs, and within all
disordered segments of the same proteins.
(C) Significance (p values) of the enrichment of
cancer-associated mutations within disordered
CREs, within disordered SLiMs, and within all
disordered segments of the same proteins.Intramolecular interactions can also occur between domains
and short linear motifs (SLiMs). SLiMs are short sequence
stretches with conserved motifs, typically 3–12 residues long,
that can mediate protein-protein interactions (Mooney et al.,
2012). To test whether the identification of SLiMs alone would
be sufficient to distinguish proteins that are regulated via interac-
tions in cis from those that are not, we searched for SLiMs in our
test datasets with the predictor SLiMpred (Mooney et al., 2012)
and the help of regular expressions from the Eukaryotic Linear
Motif (ELM) resource (Dinkel et al., 2014) (Table S5). Similar to
the results shown for the MoRF predictions, SLiMs are found in
most proteins, therefore, providing no discriminative power be-
tween the positive and negative test sets. It has to be stressed
that ‘‘ligand-binding’’ SLiMs mediate interactions with specific
domains. The concomitant occurrence of a domain and a SLiM
of any given domain-SLiM pair in the same polypeptide chain
may certainly suggest interactions in cis. This approach was
not used for Cis-regPred because most proteins in the positive
training and test sets are not interacting intramolecularly as a
result of classic domain-SLiM pairings. Nevertheless, the search
for such pairs could be complementary and implemented in a
future step.Cell Systems 2, 89–100Enrichment Analysis for CREs in
the Human Proteome
Inhibiting or activating intramolecular in-
teractions are used as a regulatory tool
in many signaling pathways (Wang
et al., 2014). However, the extent of the
usage of CREs is not known, because
no large-scale screens for these regulato-
ry elements have been possible so far.
We applied our method on human pro-
teins to provide a first map of the usage
of CREs in the human proteome.
First, we investigated which human
KEGG pathways have a significant
enrichment for proteins with CREs (Fig-
ure 3A). Among the pathways that have
an enrichment for proteins with CREs
are the well-characterized pathways of
ErbB (p = 1.0 3 108), insulin (p = 5.1 3
108), actin regulation (p = 4.6 3 107)
and MAPK (p = 1.8 3 104), in which
many autoinhibited proteins have beendiscovered before. In contrast, there is no enrichment for pro-
teins with SLiMs in these pathways when compared to all human
proteins. Interestingly, the spliceosome is also predicted to be
enriched in proteins with CREs. For years, splicing has been
studied as a modulation mechanism of autoinhibition (Druillen-
nec et al., 2012), but only recently studies emerged that reveal
the regulatory effect of CREs in splicing proteins. For instance,
the splicing protein U2AF65 is autoinhibited to avoid unwanted
splicing (Mackereth et al., 2011).
As the MAPK pathway is one of the best-studied signaling
pathways that Cis-regPred predicts to be enriched in proteins
with CREs, we investigated it in further detail and found that 75
of the 231 proteins in this pathway (32%) are predicted to contain
CREs (from receptor proteins to effector transcription factors). In
order to validate these predictions, we searched our training and
test sets as well as the literature for evidence of regulation via in-
tramolecular interactions in MAPK pathway proteins (Table 1;
Figure 4). We found 28 proteins (12%) with disordered CREs
and 40 proteins (17%) with structured CREs. 19 out of the 28
known disordered CREs were correctly identified by Cis-
regPred. Interestingly, Cis-regPred also identified 16 CREs
correctly that were classified as structured because their, February 24, 2016 ª2016 The Authors 93
Table 1. Autoinhibited Proteins in the MAP Kinase Signaling
Pathwaya
Node in
Figure 4 Nameb UniProt
Predicted
CREs
Known
AIMsc
AKT AKT1 P31749 81–170,
403–480
17–149(D)
AKT2 P31751 75–166,
403–481
17–151(D)
AKT3 Q9Y243 73–165,
398–479
17–147(S)
ATF-2 ATF2 P15336 250–374 349–415(D)
CREB ATF4 P18848 186–279
RafB BRAF P15056 296–477,
700–766
235–282(S)
CACN CACNG4 Q9UBN1 196–286
CACNG6 Q9BXT2 1–58
Cdc25B CDC25B P30305 11–412
CrkII CRK P46108 239–294(S)
CRKL P46109 162–248 129–175(S)
EGFR EGFR P00533 1047–1200 965–998(S)
Elk-1 ELK1 P19419 69–428 351–399(D)
Sap1a ELK4 P28324 71–431 156–214(D)
FGF FGF21 Q9NSA1 118–209
FGF4 P08620 19–90
FGFR FGFR1 P11362 102–193,
372–500,
551–626,
741–822
120–149(D)
FGFR2 P21802 108–233,
371–501,
744–821
125–144(D)
FGFR3 P22607 1–87,
100–234,
371–500,
729–806
126–145(D)
FGFR4 P22455 1–72, 91–187,
363–610,
727–802
119–138(D)
FLNA FLNA P21333 2142–2235(S)
HSP72 HSPA8 P11142 263–287(S)
IKK IKBKB O14920 638–727
IKBKG Q9Y6K9 343–414
IL1R IL1R1 P14778 19–102,
512–569
IL1R2 P27930 1–59,
256–326
MEK1 MAP2K1 Q02750 1–89,
249–331,
350–393
75–102(S)
MEK2 MAP2K2 P36507 1–92,
256–337,
355–400
75–102(S)
MKK3 MAP2K3 P46734 1–137 71–98(S)
MKK4 MAP2K4 P45985 1–123 109–136(S)
Table 1. Continued
Node in
Figure 4 Nameb UniProt
Predicted
CREs
Known
AIMsc
MEK5 MAP2K5 Q13163 27–201,
399–448
MKK6 MAP2K6 P52564 1–127,
269–334
MKK7 MAP2K7 O14733 1–144,
364–419
MEKK1 MAP3K1 Q13233 1–362(D),
554–581(S)
MLK3 MAP3K11 Q16584 1–132,
360–847
43–103(S)
NIK MAP3K14 Q99558 121–318(D)
MEKK2/3 MAP3K2 Q9Y2U5 1–95,
100–428
MAP3K3 Q99759 92–385
MEKK4 MAP3K4 Q9Y6R4 1223–1306 253–552(S)
ASK1 MAP3K5 Q99683 922–1077 1–648(S)
ASK2 MAP3K6 O95382 1–637(S)
TAK1 MAP3K7 O43318 296–495 1–22(D)
Tpl2/Cot MAP3K8 P41279 395–467(D)
HPK1 MAP4K1 Q92918 267–507,
545–629
474–687(S)
GCK MAP4K2 Q12851 259–489 466–670(S)
GLK MAP4K3 Q8IVH8 286–567 511–735(S)
HGK MAP4K4 O95819 290–361,
487–752,
765–891
ERK MAPK1 P28482 173–196(S)
p38 MAPK11 Q15759 1–42,
225–364
MAPK12 P53778 1–50,
279–367
MAPK13 O15264 312–365
ERK5 MAPK7 Q13164 409–575(D),
713–816(D)
JIP1/2 MAPK8IP1 Q9UQF2 495–544(S)
JNK MAPK9 P45984 304–424
MAPKAPK MAPKAPK2 P49137 1–91,
302–400
339–353(D)
MAPKAPK3 Q16644 1–68,
288–382
344–382(D)
PRAK MAPKAPK5 Q8IW41 1–44,
286–444
308–368(S)
MEF2C MEF2C Q06413 71–90(D)
Mos MOS P00540 1–81
c-Myc MYC P01106 1–353(D)
NF1 NF1 P21359 833–911,
2467–2610,
2784–2839
NFkB NFKB1 P19838 434–968(S)
NFKB2 Q00653 455–900(S)
(Continued on next page)
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Table 1. Continued
Node in
Figure 4 Nameb UniProt
Predicted
CREs
Known
AIMsc
TrkA/B NTRK1 P04629 458–527 287–384(S)
NTRK2 Q16620 433–554 298–377(S)
PAK1/2 PAK1 Q13153 1–301,
500–545
83–149(D)
PAK2 Q13177 1–101,
103–267
83–110(S)
PDGF PDGFB P01127 160–241
PDGFR PDGFRA P16234 528–604,
950–1089
999–1089(D)
PDGFRB P09619 37–140,
254–326,
397–517,
535–786,
947–1106
1060–1106(D)
cPLA2 PLA2G4C Q9UP65 1–54,
262–368
PLA2G4D Q86XP0 1–49,
98–176,
189–293,
520–605,
667–818
PPP3C PPP3CA Q08209 372–450,
464–521
467–491(D)
PPP3CC P48454 1–42,
344–512
PP5 PPP5C P53041 487–499(S)
PKA PRKACA P17612 1–63,
296–351
PKC PRKCA P17252 1–53,
143–365,
602–672
19–37(S)
PRKCB P05771 1–58,
61–130,
168–367,
585–671
19–37(S)
PRKCG P05129 18–36(S)
Raf1 RAF1 P04049 171–372,
580–648
334–345(D)
RasGRP RASGRP1 O95267 146–219,
598–734
468–609(S)
RASGRP2 Q7LDG7 337–551(S)
RASGRP3 Q8IV61 388–546(S)
RASGRP4 Q8TDF6 386–593(S)
RelA/B RELA Q04206 9–80,
241–541
313–550(D)
RSK2 RPS6KA1 Q15418 687–706(S)
RPS6KA2 Q15349 687–704(S)
RPS6KA3 P51812 694–711(S)
MSK1/2 RPS6KA4 O75676 689–703(D)
RPS6KA5 O75582 714–802 702–723(S)
Ras RRAS2 P62070 150–204
SOS SOS1 Q07889 1–198(S)
Table 1. Continued
Node in
Figure 4 Nameb UniProt
Predicted
CREs
Known
AIMsc
MST1/2 STK3 Q13188 1–53,
257–491
279–435(D)
STK4 Q13043 1–47,
270–487
282–431(D)
TAO1/2 TAOK2 Q9UL54 393–478
TGFB TGFB2 P61812 20–129,
207–341
TGFBR TGFBR1 P36897 129–226
TGFBR2 P37173 165–269,
327–567
p53 TP53 P04637 364–393(D)
TRAF6 TRAF6 Q9Y4K3 346–522(S)
MLTK ZAK Q9NYL2 539–800
aAll proteins include autoinhibitory modules (AIMs).
bProteins whose predicted CREs overlap with known disordered AIMs
are highlighted in italics.
cS (structured) denotes that the fraction of disordered residues within the
assigned region is <50%; otherwise, D (disordered).predicted disorder is <50%. The reason for this is that the CREs
of these 16 proteins also contain disordered regions, and Cis-re-
gPred identified these disordered regions. This analysis shows
that although the 32% of predicted proteins with CREs in the
MAPK pathway appears initially high, it is proportionate to the
number of proteins with CREs in this pathway that have already
been discovered.
Next, we predicted CREs for the entire human proteome
and found that 4,933 of 16,539 proteins (30%) contain disor-
dered CREs (see Experimental Procedures for human protein
selection criteria). Human proteins with predicted CREs have
an enriched occurrence in diverse biological processes
including transcription, translation, protein transport or protein
complex assembly (Figure S4A). Moreover, CREs are more
likely to be found in proteins that contain domains such as
the Ets, SAM, SH3, FERM or kinase domains (Figures S4B
and S4C).
Overall, these analyses suggest that CREs are used for protein
regulation in very diverse processes and that Cis-regPred
may become a useful tool in prioritizing targets for the complete
mapping of the human ‘‘cis regulome.’’ That 30% of all human
proteins contain CREs may be a favorable estimate. However,
it has already been proven experimentally (green and blue pro-
teins in Figure 4; Hansen and Kwiatkowski, 2013) that CREs
are very abundantly used in certain signaling pathways, which
we found also enriched in predicted CREs.
CREs and Human Disease
Proteins with large intrinsically disordered regions have been
associated with various human diseases (Iakoucheva et al.,
2002) and have been shown to be tightly regulated in their avail-
ability (Babu et al., 2011; Gsponer et al., 2008), probably due to
an increased dosage sensitivity (Vavouri et al., 2009). Interest-
ingly, intrinsically disordered protein regions as a whole are not
enriched in disease mutations (Pajkos et al., 2012). Neither hasCell Systems 2, 89–100, February 24, 2016 ª2016 The Authors 95
Figure 4. Map of Known and Predicted CREs within Proteins of the MAP Kinase Signaling Pathway
Proteins with predicted disordered CREs are circled in magenta. Proteins with known disordered and structured CREs are green and blue, respectively. The
known CREs in this figure have an inhibitory function. Nodes in this figure were adopted from the KEGG pathway and thus may represent one or more proteins.
For instance, the AKT node includes three proteins (At1, Akt2, and Akt3). All these proteins have CREs, but some are structured, whereas some are disordered. In
this case, the node is black. Detailed prediction results and known CRE information are summarized in Table 1.an enrichment for disease mutations been reported for the func-
tionally important SLiMs in intrinsically disordered regions,
though missense mutations when occurring in SLiMs are more
often disease-related than neutral (Uyar et al., 2014). We
wondered whether disease-related mutations are enriched in
CREs and undertook a first pilot study to answer this question
by mapping mutation data from SwissVar (Mottaz et al., 2010)
onto the 16,539 human proteins fromUniProt. Using a hypergeo-
metric test, we then assessed the statistical enrichment of muta-
tions within predicted disordered CREs when compared to the
total number of mutations in each protein. The analysis revealed
that disease-associated mutations are highly enriched within
predicted CREs (p = 4.7 3 10101; Figure 3B), while they
are not generally enriched in intrinsically disordered parts of
the same proteins (p = 1.0) or within their SLiMs (p = 0.011).
This finding underlines the functional importance of the
intrinsically disordered sequence stretches that are identified96 Cell Systems 2, 89–100, February 24, 2016 ª2016 The Authorsby Cis-regPred and provides indirect support for the method’s
accuracy.
As disruption of autoinhibition has specifically been linked to
various cancers, we also analyzed which cancer-associated
mutations are enriched in CREs. Cancer-associated mutations
were obtained from Catalogue of Somatic Mutations in Cancer
(COSMIC) (Forbes et al., 2008). COSMIC categorizes mutations
into 84 different histological types according to the samples
studied. Our analysis reveals that particularly mutations that
lead to primitive neuroectodermal tumor (p = 2.63 106), cranio-
pharyngioma (p = 5.0 3 106), adnexal tumor (p = 4.9 3 105),
and adenoma (p = 9.2 3 105) are highly associated with pre-
dicted CREs (Figure 3C). Proteins that have primitive neuroecto-
dermal tumor–associated mutations within predicted CREs are
depicted in Figure S5.
We also found various literature reports of mutations in pre-
dicted CREs that are associated with cancer. For instance, the
disordered CRE of CAMKK2 was correctly predicted by our
method (Figure 2) and mutations within the known CRE were
found in esophageal adenocarcinoma andmetastatic melanoma
(Berger et al., 2012; Dulak et al., 2013). Moreover, we predicted
disordered CREs in FGFR1 andmutations within these CREs are
found in patients with urothelial carcinoma (Ross et al., 2014) and
Kallmann syndrome (Albuisson et al., 2005). As a mutagenesis
study showed that mutations within the CREs released the
autoinhibition of FGFR1, the mutations found in the patients
are likely to be associated with disrupted autoinhibition (Olsen
et al., 2004). A homolog of FGFR1, FGFR4, was predicted to
have disordered CREs, in which gain-of-function mutations
were found that are associated with lung cancer (Fawdar et al.,
2013).
Overall, these analyses demonstrate a strong association
of the predicted CREs with disease-causing genetic variations.
Therefore, our method should be useful for the generation
of hypotheses regarding the functional impact of variations in
gene regions that encode intrinsically disordered segments of
proteins.
DISCUSSION
Transient protein-protein interactions are key to signal integra-
tion and decision making in the cell. To map these protein inter-
actions, various high-throughput experimental (Hosp et al.,
2015) and computational (Kotlyar et al., 2015) methods have
been developed and applied. The steadily growing number of
signaling proteins whose function is also regulated via intramo-
lecular interactions, particularly in the form of autoinhibition (Pu-
fall and Graves, 2002), implies that interactions in cis may be
equally important in signal integration as interactions in trans.
Here we introduce the computational tool Cis-regPred for pre-
dicting whether a polypeptide chain has sequence elements that
mediate intramolecular interactions, i.e., whether the protein is
regulated via interactions in cis. The accuracy of Cis-regPred is
similar to the accuracy of state-of-the art computational
methods predicting protein interactions in trans.Weused Cis-re-
gPred to generate a map of the ‘‘cis regulome’’ in the MAPK
pathway and correctly identified 19 out of 28 known disordered
AIMs in the proteins of this pathway. When applied on the com-
plete human proteome, 30% of the proteins are predicted to
contain disordered CREs. It remains to be proven experimentally
whether the number of proteins with CREs is in fact that high.
Nevertheless, our analysis on the MAPK pathway and data
from others clearly show that the prevalence of CREs in certain
signaling pathways is high (Hansen and Kwiatkowski, 2013;
Huse and Kuriyan, 2002).
Predictions of the location of CREs become very valuable
when matched with data on genetic alterations that are linked
to human disease. We demonstrate that Cis-regPred identifies
disordered protein parts that are highly enriched in disease-
associated mutations, which provides further indirect evidence
for the functional importance of the intrinsically disordered pro-
tein parts that are selected. Consequently, this tool should help
provide a more comprehensive view of the prevalence of cis
regulation in various cellular processes, particularly in signal inte-
gration, and foster the identification of genetic alterations that
perturb this vital process in human disease.EXPERIMENTAL PROCEDURES
Datasets
See Supplemental Experimental Procedures for details on datasets.
Features
We prepared 1,040 feature types related to diverse physico-chemical and sta-
tistical properties that may be enriched in disordered AIMs: hydrophobicity
(Chen and Jeong, 2009), number of phosphorylation sites (Hornbeck et al.,
2012), secondary structure (Buchan et al., 2013), splicing isoforms, amino
acid compositions, amino acid flexibility (Yachdav et al., 2014), solvent acces-
sibility (Yachdav et al., 2014), and others (Figure 1B; Table S3). For a given pro-
tein sequence, disorder propensity was first predicted by using four tools: Pre-
dictProtein (Yachdav et al., 2014), RONN (Yang et al., 2005), DisoPred2 (Ward
et al., 2004), and IUPred (Doszta´nyi et al., 2005). A residue was marked as
disordered if any of the four predictors identified the residue as disordered.
If a continuous disordered sequence was longer than nine residues, which is
the shortest CRE length in our dataset, the sequence was considered as a po-
tential CRE segment. Using sliding windows of size n and the 1,040 features,
we then calculated position-specific and window-averaged feature scores
(Figure 1B) for the potential CRE segments. In the case of a window size of
15, each residue has 9,078 feature scores from the 1,040 feature types. For
instance, for a give window size of 5, the amino acid Thr in Figure 1B has
five position-specific disorder propensity scores and one additional averaged
disorder propensity score within the window, one single score for the number
of phosphorylation sites within the window, and one single globularity score for
the protein sequence. The full list of scores calculated for each residue, win-
dow, and protein is shown in Table S3 and selected features are shown in
Table S4.
Development of Cis-regPred
To develop Cis-regPred, we used a training and testing structure that is nearly
identical to the one suggested in a recent review on correct machine learning
approaches in protein sequence-based predictions (see Figure 5 in Walsh
et al., 2015). The training data was split in a 10-fold cross-validation procedure
to first do feature selection and parameter tuning and then evaluation of the
ten generated models on the cross-validation sets. Hence, all parameters,
including features, were tuned and selected on the training set only. As the
feature list that we initially created was very large—too large for combinatorial
testing—we first ranked the normalized feature scores according to their cor-
relation with the location of disordered CREs: point-biserial correlation coeffi-
cient for continuous scores and phi coefficient for binary scores (Chen and
Jeong, 2009). The 400 feature scores with highest correlation were then
used in the training of a multiple linear regression (MLR) model with the help
of the data-mining tool Orange (Demsar et al., 2013). We identified the optimal
MLR model in a feature selection process in which we used different numbers
of top-ranked features (f = 5–400) and window sizes (n = 3–41) as input. During
this process, the LASSO method was applied to exclude unrelated features
(Ghosh and Chinnaiyan, 2005). The quality of optimal models was then as-
sessed on the ten cross-validation sets (as suggested in Figure 5 in Walsh
et al., 2015). A window size of 15 and the use of 44 features provided the high-
est AUC (see Figure 1C). A stretch of residues with prediction scores over a
selected cutoff value and longer than nine amino acids was considered as a
disordered CRE. An important fact to note is that it can be difficult to define
the boundary of disordered CREs. CREs are experimentally often identified
by assaying different deletion constructs. Putative CREs that are removed in
these constructs can vary significantly in size and range from a few residues
to hundreds of residues. If the deletion construct has altered activity, the entire
deleted region is commonly defined as CRE. Consistently, the shortest disor-
dered CRE in our dataset is 9 residues long, and the average CRE length is
86.0 ± 68.8 residues (mean ± SD). Hence, most CREs identified experimentally
contain amino acid residues directly involved in cis interaction but also others
that may not be. Therefore, we also assigned segments (30 residues) on either
side of the amino acids with the highest prediction score as part of the CRE.
Consistent with the suggestion made by Walsh et al. for the use of machine
learning methods on imbalanced datasets—many negative cases (here, disor-
dered regions without CREs) and few positives (CREs)—we selected a cutoff
of 0.3 at which Cis-regPred identifies disordered CREs in the training set with aCell Systems 2, 89–100, February 24, 2016 ª2016 The Authors 97
high per-residue specificity (0.97). The sensitivity is 0.45, the accuracy 95.7%,
and the TDR 0.19 at this cutoff. The per-protein prediction accuracy on the
training set is then 89.0%, the sensitivity 0.32, the specificity 0.97, and the
TDR 0.57.
Evaluation of Cis-regPred
Besides the assessment with the help of the cross-validation sets, the MLR
models were also validated on independent positive and negative test sets
(see Supplemental Experimental Procedures). Due to the 10-fold cross-valida-
tion approach, ten models were produced in training. We use them all on the
test sets and report the averaged results in Table S5. However, it has to be
stressed that ten models are not useful when running a server. Therefore,
we reparameterized a final model for the Cis-regPred server with the selected
44 features on the entire training set and report the performance of this model
on the test set in the main text and in Table S5. The difference between the
average performance of the ten learnedmodels and the performance of the re-
trained final model (Cis-regPred) is very small. During evaluation, we also as-
sessed the performance of Cis-regPred when not including the 30 residues
on either side of the amino acids with the highest prediction score. In this
case, the per-protein AUC drops to 0.71.
To assess potential overfitting, we calculated the AUC on actual training sub-
sets (parts of the trainingset used for trainingandnot cross-validation), the cross-
validation sets, and the test set as a function of an increasing number of selected
features. A significantly lower performance on the evaluation set(s) compared to
the training set is a main indicator of overfitting (‘‘generalization drop’’).
Association Analysis of CRE and Human Diseases
We collected human proteins from UniProt database and discarded se-
quences that are shorter than 100 residues or that contain unidentified resi-
dues. This provided 16,539 human proteins. Protein mutation data and their
associated diseases were obtained from the SwissVar (July 2014) (Mottaz
et al., 2010) and mutations were mapped onto the 16,539 human proteins ob-
tained from UniProt. Of the diverse mutations, we used only single point mu-
tations because deletion or insertion mutations may change the whole protein
sequence, and multiple mutations at the same sequence position were
counted as only one mutation that affects a given sequence portion. Enrich-
ment of mutations within predicted disordered CREs, SLiMs and all disordered
parts were assessed using a hypergeometric test when compared with the to-
tal number of mutations within the proteins.
Association of cancer mutations with disordered CREs was assessed with
the mutation data obtained from Catalogue of Somatic Mutations in Cancer
(COSMIC) (Forbes et al., 2008) in July 2014. We assessed the enrichment of
cancer histological types categorized in COSMIC. As was done for SwissVar,
we collected only single point mutations, discarded redundant mutations, and
compared mutations within disordered CREs, SLiMs and all disordered parts
with those occurring in the entire protein using hypergeometric test.
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